Orchestra BioMed Holdings Inc. (OBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has a cash flow conversion efficiency ratio of -0.657x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.33 Million) by net assets ($29.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Orchestra BioMed Holdings Inc. market capitalisation for the company's overall valuation and market capitalisation.
Orchestra BioMed Holdings Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Orchestra BioMed Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Orchestra BioMed Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their cash flow conversion efficiency. Explore Orchestra BioMed Holdings Inc. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Fjr Optoelectronic Technology Co Ltd
SHG:688272
|
-0.043x |
|
Pinlive Foods Co Ltd
SHE:300892
|
0.009x |
|
Zhejiang Canaan Technology Co Ltd
SHE:300412
|
0.075x |
|
VRG SA
WAR:VRG
|
0.016x |
|
Top Gum Industries Ltd
TA:TPGM
|
0.020x |
|
Orion Engineered Carbons SA
F:0OE
|
0.242x |
|
Computer Direct
TA:CMDR
|
0.082x |
|
Daqing Huake Co Ltd
SHE:000985
|
0.076x |
Annual Cash Flow Conversion Efficiency for Orchestra BioMed Holdings Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Orchestra BioMed Holdings Inc. from 2020 to 2025. View Orchestra BioMed Holdings Inc. (OBIO) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $63.38 Million | $-48.96 Million | -0.773x | +49.64% |
| 2024-12-31 | $32.96 Million | $-50.56 Million | -1.534x | -126.29% |
| 2023-12-31 | $68.04 Million | $-46.13 Million | -0.678x | -21.59% |
| 2022-12-31 | $52.53 Million | $-29.29 Million | -0.558x | -304.40% |
| 2021-12-31 | $-71.23 Million | $-19.43 Million | 0.273x | -49.43% |
| 2020-12-31 | $-48.54 Million | $-26.18 Million | 0.539x | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more